Skin Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SKN013 MIFTS: 51	Skin Benign Neoplasm Categories: Cancer diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Skin Benign Neoplasm

MalaCards integrated aliases for Skin Benign Neoplasm:

Name: Skin Benign Neoplasm ¹¹ ¹⁴

Neoplasm of Skin by Site ¹¹

Benign Neoplasm of Skin ⁷¹

Tumor of the Skin ¹¹

Skin Neoplasms ⁷¹

Skin Tumor ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Benign neoplasms

Other benign neoplasms of skin

Benign neoplasm: Skin, unspecified

External Ids:

Disease Ontology ¹¹ DOID:3165

MeSH ⁴³ D012878

NCIt ⁴⁹ C3372

SNOMED-CT ⁶⁸ 126488004

ICD10 ³¹ D23.9

UMLS ⁷¹ C0004998 C0037286

Sources

Summaries for Skin Benign Neoplasm

MalaCards based summary: Skin Benign Neoplasm, also known as neoplasm of skin by site, is related to malignant syringoma and skin papilloma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Benign Neoplasm is KRT14 (Keratin 14), and among its related pathways/superpathways are Breast cancer pathway and G-Beta Gamma Signaling. The drugs Etanercept and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells, and related phenotypes are homeostasis/metabolism and growth/size/body region

Sources

Related Diseases for Skin Benign Neoplasm

Diseases related to Skin Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)

#	Related Disease	Score	Top Affiliating Genes
1	malignant syringoma	32.0	KRT5 KRT20
2	skin papilloma	32.0	STAT3 ODC1 KRT14 KRT1 HRAS
3	cowden syndrome 1	31.7	MSH6 MSH2 MLH1 HRAS FLCN
4	mixed cell type cancer	31.5	SERPINA3 MLH1 KRT5 HRAS
5	papilloma	31.0	TP63 ODC1 KRT5 KRT20 KRT14 KRT1
6	skin carcinoma	30.8	XPA PTCH1 ODC1 MSH2 KRT5 KRT20
7	muir-torre syndrome	30.6	MSH6 MSH2 MLH1 KRT5 HRAS
8	keratoacanthoma	30.5	TP63 STAT3 MSH2 MLH1 KRT14
9	keratosis	30.4	KRT5 KRT14 KRT1 HRAS FGFR3
10	actinic keratosis	30.4	XPA TP63 KRT14
11	xeroderma pigmentosum, variant type	30.3	XPA PTCH1 MSH6 MSH2 MLH1
12	meningioma, familial	30.3	SERPINA3 PTCH1 ODC1 HRAS GLI2 GLI1
13	neurofibromatosis	30.3	MSH6 MSH2 MLH1 HRAS BRAF
14	polycystic liver disease 1 with or without kidney cysts	30.3	PTCH1 KRT20 FLCN
15	neurofibromatosis, type i	30.2	MSH6 MSH2 MLH1 HRAS
16	skin squamous cell carcinoma	30.2	MSH6 MSH2 MLH1 KRT5 KRT14 HRAS
17	epithelial-myoepithelial carcinoma	30.1	KRT5 KRT14
18	cutaneous leiomyosarcoma	30.1	KRT5 FLCN
19	dysplastic nevus syndrome	30.1	MSH6 MSH2 MLH1
20	melanoma, cutaneous malignant 1	30.1	MSH6 MSH2 MLH1 HRAS BRAF
21	adenoma	30.0	MSH6 MSH2 MLH1 KRT20 HRAS BRAF
22	sebaceous adenocarcinoma	30.0	MSH6 MSH2 MLH1 KRT5 KRT14
23	squamous cell carcinoma	29.9	TP63 STAT3 KRT14 HRAS FGFR3 BRAF
24	sebaceous adenoma	29.9	SERPINA3 MSH6 MSH2 MLH1 KRT14
25	basal cell nevus syndrome	29.9	PTCH1 HRAS GLI2 GLI1
26	epithelioid sarcoma	29.8	TP63 SERPINA3 KRT20 KRT14 KRT1
27	basal cell carcinoma	29.8	XPA TP63 STAT3 PTCH1 MSH2 MLH1
28	adenoid cystic carcinoma	29.8	TP63 SERPINA3 KRT20 KRT14 HRAS
29	cowden syndrome	29.8	PTCH1 MSH6 MSH2 MLH1 HRAS FLCN
30	wilms tumor 1	29.8	SERPINA3 KRT5 HRAS BRAF
31	lynch syndrome	29.8	XPA MSH6 MSH2 MLH1 HRAS BRAF
32	familial adenomatous polyposis	29.8	ODC1 MSH6 MSH2 MLH1 HRAS BRAF
33	intestinal benign neoplasm	29.8	STAT3 SERPINA3 MSH6 MSH2 MLH1 HRAS
34	skin disease	29.7	TP63 STAT3 SERPINA3 PTCH1 KRT5 KRT14
35	brain cancer	29.7	STAT3 PTCH1 MSH6 MSH2 GLI1 BRAF
36	colonic benign neoplasm	29.6	STAT3 SERPINA3 ODC1 MSH6 MSH2 MLH1
37	squamous cell carcinoma, head and neck	29.6	TP63 STAT3 MLH1 HRAS FGFR3 BRAF
38	lung cancer susceptibility 3	29.5	TP63 STAT3 MLH1 KRT20 HRAS FGFR3
39	bladder cancer	29.3	TP63 STAT3 PTCH1 MSH2 MLH1 KRT20
40	pancreatic cancer	29.2	STAT3 SERPINA3 PTCH1 MSH6 MSH2 MLH1
41	breast cancer	29.1	TP63 STAT3 SERPINA3 ODC1 MSH6 MSH2
42	skin lipoma	11.1
43	malignant granular cell skin tumor	11.0
44	genetic skin tumor or hamartoma	11.0
45	rare skin tumor or hamartoma	11.0
46	keratosis, seborrheic	10.9
47	birt-hogg-dube syndrome	10.9
48	brooke-spiegler syndrome	10.9
49	paget disease, extramammary	10.8
50	discoid fibromas, familial multiple	10.8

Graphical network of the top 20 diseases related to Skin Benign Neoplasm:

Sources

Symptoms & Phenotypes for Skin Benign Neoplasm

UMLS symptoms related to Skin Benign Neoplasm:

pruritus; exanthema

GenomeRNAi Phenotypes related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	BRAF FGFR3 FLCN GLA GLI1 GLI2
2	no effect	GR00402-S-2	10.2	BRAF FGFR3 FLCN GLA GLI1 GLI2

MGI Mouse Phenotypes related to Skin Benign Neoplasm:

⁴⁵ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.41	BRAF FGFR3 FLCN GLA GLI2 HRAS
2	growth/size/body region	MP:0005378	10.4	BRAF FGFR3 FLCN GLA GLI1 GLI2
3	neoplasm	MP:0002006	10.38	BRAF FGFR3 FLCN GLI1 HRAS KRT14
4	cellular	MP:0005384	10.28	BRAF FGFR3 FLCN GLA GLI1 GLI2
5	immune system	MP:0005387	10.24	BRAF FGFR3 FLCN GLA KRT1 KRT14
6	digestive/alimentary	MP:0005381	10.23	BRAF FGFR3 GLI1 GLI2 HRAS KRT14
7	normal	MP:0002873	10.21	BRAF FGFR3 GLI1 GLI2 HRAS ODC1
8	renal/urinary system	MP:0005367	10.2	BRAF FGFR3 FLCN GLA GLI1 HRAS
9	endocrine/exocrine gland	MP:0005379	10.18	BRAF GLI1 GLI2 HRAS KRT14 MLH1
10	craniofacial	MP:0005382	10.17	BRAF FGFR3 GLI1 GLI2 HRAS KRT14
11	muscle	MP:0005369	10.14	BRAF GLA GLI2 HRAS PTCH1 STAT3
12	limbs/digits/tail	MP:0005371	10.13	BRAF FGFR3 GLI1 GLI2 KRT5 PTCH1
13	respiratory system	MP:0005388	10.06	BRAF FGFR3 GLI1 GLI2 HRAS KRT14
14	reproductive system	MP:0005389	9.96	BRAF FGFR3 GLI1 GLI2 KRT14 MLH1
15	hematopoietic system	MP:0005397	9.93	BRAF FGFR3 FLCN KRT1 KRT14 MLH1
16	mortality/aging	MP:0010768	9.91	BRAF FGFR3 FLCN GLA GLI1 GLI2
17	integument	MP:0010771	9.5	BRAF FGFR3 GLI2 HRAS KRT1 KRT14

Sources

Drugs & Therapeutics for Skin Benign Neoplasm

Drugs for Skin Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Etanercept

Approved, Investigational

Phase 4

185243-69-0

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Azathioprine

Approved

Phase 4

446-86-6

2265

Mycophenolic acid

Approved, Investigational

Phase 4

24280-93-1

446541

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Tin Fluorides

Phase 4

Anti-Infective Agents

Phase 4

Antimetabolites

Phase 4

Immunosuppressive Agents

Phase 4

Immunologic Factors

Phase 4

Neurotransmitter Agents

Phase 4

Dermatologic Agents

Phase 4

Anti-Bacterial Agents

Phase 4

Calcineurin Inhibitors

Phase 4

Cyclosporins

Phase 4

Antifungal Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Agglutinins

Phase 4

abobotulinumtoxinA

Phase 4

Botulinum Toxins, Type A

Phase 4

Botulinum Toxins

Phase 4

Hemagglutinins

Phase 4

Cholinergic Agents

Phase 4

Eflornithine

Approved, Withdrawn

Phase 3

70052-12-9

3009

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Acetaminophen

Approved

Phase 3

103-90-2

1983

Nivolumab

Approved

Phase 3

946414-94-4

Dimethyl sulfoxide

Approved, Vet_approved

Phase 3

67-68-5

679

Trametinib

Approved

Phase 3

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 3

1195765-45-7

44462760

Ipilimumab

Approved

Phase 3

477202-00-9

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 3

1187560-31-1

Temozolomide

Approved, Investigational

Phase 3

85622-93-1

5394

Dacarbazine

Approved, Investigational

Phase 3

4342-03-4

2942 5351166

Ornithine

Approved, Nutraceutical

Phase 3

3184-13-2, 70-26-8

6262

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Sunscreening Agents

Phase 2, Phase 3

Methyl 5-aminolevulinate

Phase 3

Monatide (IMS 3015)

Phase 3

Freund's Adjuvant

Phase 3

Radiation-Protective Agents

Phase 2, Phase 3

Antipyretics

Phase 3

Vitamins

Phase 3

Trace Elements

Phase 3

Antioxidants

Phase 3

Interventional clinical trials:

(show top 50) (show all 501)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation	Unknown status	NCT03767660	Phase 4	Rapamycin
2	CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial	Completed	NCT00847912	Phase 4	5-fluorouracil;Placebo, vehicle control
3	A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen	Completed	NCT00129961	Phase 4	sirolimus;cyclosporine or tacrolimus
4	Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients	Completed	NCT00492895	Phase 4	Discontinuation of Azathioprin
5	Can We Miss Pigmented Lesions in Psoriasis Patients?	Completed	NCT01053819	Phase 4	etanercept
6	Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study	Recruiting	NCT04056962	Phase 4	Tacrolimus ointment
7	Safety and Efficacy of Photodynamic Therapy With Aminolevulinic Acid 10% Topical Gel Activated by Red Light Versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study	Not yet recruiting	NCT05359419	Phase 4
8	Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol	Terminated	NCT00866684	Phase 4	Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
9	Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol	Terminated	NCT01797315	Phase 4	Sirolimus
10	A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer	Terminated	NCT01459666	Phase 4	Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
11	CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial	Unknown status	NCT00799188	Phase 3	Everolimus
12	CSP #402 - VA Topical Tretinoin Chemoprevention Trial	Completed	NCT00007631	Phase 3	Tretinoin 0.1% cream or placebo
13	Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage.	Completed	NCT00224744	Phase 3
14	A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma	Completed	NCT01989572	Phase 3
15	A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer	Completed	NCT00472459	Phase 3
16	Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors	Completed	NCT00133887	Phase 3	rapamycin;ciclosporine;tacrolimus
17	A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma	Completed	NCT00066872	Phase 3	imiquimod
18	A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma	Completed	NCT00110019	Phase 3	Carboplatin;Paclitaxel;Sorafenib Tosylate
19	Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial	Completed	NCT00005884	Phase 3	eflornithine
20	Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers	Completed	NCT03131713	Phase 3	Acetaminophen
21	Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00193895	Phase 3	Carboplatin
22	Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery	Completed	NCT00367042	Phase 2, Phase 3
23	A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma	Completed	NCT00019682	Phase 3	Montanide ISA 51 VG
24	A Randomized Control Trial of Sun Protection Interventions for Operating Engineers	Completed	NCT01804595	Phase 2, Phase 3
25	Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial	Completed	NCT04549675	Phase 3
26	Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II)	Recruiting	NCT03860883	Phase 3
27	A Personalized Approach to Skin Cancer Prevention Among Adolescents	Recruiting	NCT04341064	Phase 3
28	Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma	Recruiting	NCT02339571	Phase 2, Phase 3
29	A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma	Active, not recruiting	NCT02385214	Phase 3
30	A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma	Active, not recruiting	NCT02506153	Phase 3
31	DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial	Active, not recruiting	NCT02224781	Phase 3	Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
32	A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma	Active, not recruiting	NCT01274338	Phase 3
33	Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome	Active, not recruiting	NCT01748448	Phase 3	Vitamin D;arachides oleum raffinatum
34	Risk Information and Skin-Cancer Education and Undergraduate Prevention Trial	Not yet recruiting	NCT05634252	Phase 3
35	Prophylactic LYMphatic Reconstruction (LYMbR) to Prevent Lymphedema	Not yet recruiting	NCT05136079	Phase 3
36	PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma	Terminated	NCT02288897	Phase 3	PV-10 (10% rose bengal disodium);Dacarbazine, temozolomide or talimogene laherparepvec
37	HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	Unknown status	NCT02836548	Phase 1, Phase 2	Vorinostat
38	Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma	Unknown status	NCT00747903	Phase 2	aminolevulinic acid hydrochloride
39	A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin	Unknown status	NCT00423397	Phase 1, Phase 2	gefitinib
40	Skin Cancer Prophylaxis by Low-Fat Dietary Intervention	Unknown status	NCT00003097	Phase 2
41	A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma	Unknown status	NCT00925314	Phase 2
42	Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance	Unknown status	NCT03666325	Phase 2	Pembrolizumab;Cetuximab
43	Transient Infrared Imaging for Early Detection of Skin Cancer	Unknown status	NCT02154451	Phase 1, Phase 2
44	Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm	Completed	NCT00601640	Phase 2	Diclofenac Na gel;Eflornithine HCL ointment
45	A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts.	Completed	NCT02705352	Phase 2	5-Fluorouracil
46	Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma	Completed	NCT00027586	Phase 2	Imatinib mesylate (STI571)
47	Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma	Completed	NCT00094107	Phase 2	Axitinib [AG-013736]
48	Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR)	Completed	NCT00204789	Phase 2	Difluoromethylornithine
49	A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma	Completed	NCT01961115	Phase 2	Epacadostat
50	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma	Completed	NCT00804908	Phase 2	temozolomide;ABT-888

Search NIH Clinical Center for Skin Benign Neoplasm

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cholecalciferol

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

peginterferon alfa-2a

peginterferon alfa-2b

Recombinant interferon beta-1a

Recombinant interferon beta-1b

Sources

Genetic Tests for Skin Benign Neoplasm

Sources

Anatomical Context for Skin Benign Neoplasm

Organs/tissues related to Skin Benign Neoplasm:

MalaCards : Skin, Lymph Node, T Cells, Brain, Liver, Lung, Breast

Sources

Publications for Skin Benign Neoplasm

Articles related to Skin Benign Neoplasm:

(show top 50) (show all 3087)

#	Title	Authors	PMID	Year
1	A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. ⁵³ ⁶²	Mandinova A...Dotto GP	19729838	2009
2	The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis. ⁵³ ⁶²	Virador VM...Yuspa SH	19058256	2009
3	p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. ⁵³ ⁶²	Schindler EM...Efimova T	19458068	2009
4	Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. ⁵³ ⁶²	Kataoka K...DiGiovanni J	18453544	2008
5	Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. ⁵³ ⁶²	Ponti G...Seidenari S	16826164	2006
6	Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. ⁵³ ⁶²	Siren V...Vaheri A	16408192	2006
7	Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. ⁵³ ⁶²	Wilker E...DiGiovanni J	16086373	2005
8	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. ⁵³ ⁶²	Logie A...Radvanyi F	15772091	2005
9	Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. ⁵³ ⁶²	Chan KS...DiGiovanni J	15343391	2004
10	Stat3 is required for the development of skin cancer. ⁵³ ⁶²	Pedranzini L...Bromberg J	15343379	2004
11	In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. ⁵³ ⁶²	Sommer VH...Odum N	15141228	2004
12	Loss of tyrosinase activity confers increased skin tumor susceptibility in mice. ⁵³ ⁶²	Saran A...Dragani TA	15007389	2004
13	E2F modulates keratinocyte squamous differentiation: implications for E2F inhibition in squamous cell carcinoma. ⁵³ ⁶²	Wong CF...Saunders NA	12754218	2003
14	Retinoids in chemoprevention of cancer. ⁵³ ⁶²	Verma AK	12757023	2003
15	Inhibitory effect of glycolic acid on ultraviolet B-induced c-fos expression, AP-1 activation and p53-p21 response in a human keratinocyte cell line. ⁵³ ⁶²	Ahn KS...Hong JT	12213282	2002
16	Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. ⁵³ ⁶²	Sheng H...Dlugosz AA	12235001	2002
17	Overexpression of a constitutively active form of c-src in skin epidermis increases sensitivity to tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. ⁵³ ⁶²	Matsumoto T...DiGiovanni J	11870880	2002
18	Inhibition of mouse skin tumor promotion by anti-inflammatory diarylheptanoids derived from Alpinia oxyphylla Miquel (Zingiberaceae). ⁵³ ⁶²	Chun KS...Surh YJ	12201673	2002
19	The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. ⁵³ ⁶²	Atit RP...Ratner N	10844550	2000
20	Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. ⁵³ ⁶²	Wilker E...DiGiovanni J	10365914	1999
21	12-lipoxygenase expression in human melanoma cell lines. ⁵³ ⁶²	Timar J...Hagmann W	10667390	1999
22	Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. ⁵³ ⁶²	Greco A...Pierotti MA	9771975	1998
23	Differential activation of mitogen-activated protein kinases by palytoxin and ouabain, two ligands for the Na+,K+-ATPase. ⁵³ ⁶²	Li S...Wattenberg EV	9707514	1998
24	Competent transcription initiation by RNA polymerase II in cell-free extracts from xeroderma pigmentosum groups B and D in an optimized RNA transcription assay. ⁵³ ⁶²	Satoh MS...Hanawalt PC	9427533	1997
25	E2F as a regulator of keratinocyte proliferation: implications for skin tumor development. ⁵³ ⁶²	Jones SJ...Saunders NA	9242506	1997
26	The DNA repair protein O6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. ⁵³ ⁶²	Becker K...Kaina B	9269990	1997
27	Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. ⁵³ ⁶²	Katiyar SK...Mukhtar H	8640756	1996
28	Recombinagenic activity of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate in human lymphoblastoid cells. ⁵³ ⁶²	Honma M...Little JB	7634395	1995
29	Low frequency of codon 61 Ha-ras mutations and lack of keratin 13 expression in 7,12-dimethylbenz[a]-anthracene-induced hamster skin tumors. ⁵³ ⁶²	Robles AI...Conti CJ	7681292	1993
30	Periocular Merkel Cell Carcinoma - An Overview of Clinical Aspects and Current Treatment Options. ⁶²	Esser E...Mihailovic N	36368663	2022
31	[Correlation between Connexin 43 Mutation and Skin Diseases]. ⁶²	He X...Wang DH	36373638	2022
32	Cholecystokinin Receptor Antagonist Suppresses Melanoma Growth by Inducing Apoptosis of Tumor Cells. ⁶²	Funakoshi A...Tokura Y	36262666	2022
33	Delay in Seeking Medical Attention and Diagnosis in Chinese Melanoma Patients: A Cross-Sectional Study. ⁶²	Ke X...Su J	36429635	2022
34	PARP1 Is a Prognostic Marker and Targets NFATc2 to Promote Carcinogenesis in Melanoma. ⁶²	Mou K...Ge R	36394458	2022
35	Identification and Validation of a Novel Model: Predicting Short-Term Complications After Local Flap Surgery for Skin Tumor Removal. ⁶²	Zhao Z...Zhao Y	36384866	2022
36	Multiple Pyogenic Granulomas in the External Auditory Canal. ⁶²	Lee HJ...Lee JM	36433695	2022
37	Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy. ⁶²	Oertel M...Greve B	36443849	2022
38	Lipomatous mixed tumor of the skin with cystic formation affecting the upper lip: A case report. ⁶²	Nagano R...Kiyoshima T	36168412	2022
39	hsa_circ_0038382 upregulates T-box transcription factor 5 to inhibit keloid formation by interacting with miR-940. ⁶²	Cai M...Su J	36413177	2022
40	Surgical experiences in pediatric pilomatricoma: punch incision and elliptical excision. ⁶²	Choi H...Kim MS	36214494	2022
41	Giant pilomatrixoma with bullous appearance on the back: A case report and discussion of misdiagnosis. ⁶²	Yu N...Zhang Q	35332644	2022
42	Human papillomavirus 42 drives digital papillary adenocarcinoma and elicits a germ-cell like program conserved in HPV-positive cancers. ⁶²	Leiendecker L...Obenauf AC	36213965	2022
43	Combination of Optical Biopsy with Patient Data for Improvement of Skin Tumor Identification. ⁶²	Khristoforova Y...Zakharov V	36292192	2022
44	Reconstruction of Head and Neck Region with Supraclavicular Artery Flap. ⁶²	Ucak M	36452613	2022
45	Usefulness of ultrasonography in the preoperative diagnosis of mixed tumor of the skin (chondroid syringoma): A case series with nine patients. ⁶²	Mitsui Y...Asada H	35718945	2022
46	Skin endothelial cell and microcirculation function study in recurred keloids patients after keloid surgery and radiotherapy. ⁶²	Li W...Qiu J	36316928	2022
47	Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis. ⁶²	Al Moussawi K...Lu X	36261000	2022
48	The Use of Matriderm® for Scalp Full-Thickness Defects Reconstruction: A Case Series. ⁶²	Dell'Aversana Orabona G...Califano L	36294362	2022
49	[Clinical effects of lateral supramalleolar perforator island flaps with low rotation points in repairing foot skin and soft tissue defect wounds]. ⁶²	Chen LM...Liu Y	36299204	2022
50	Tumor Doubling Time in Skin Cancer: Can It Be Estimated and Is it Useful? ⁶²	Tejera-Vaquerizo A...Nagore E	36273551	2022

Sources

Genes for Skin Benign Neoplasm

Genes related to Skin Benign Neoplasm (0 elite genes):

(show all 37)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	KRT14	Keratin 14	Protein Coding	14.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14744767
2	KRT5	Keratin 5	Protein Coding	13.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16086373 19058256
3	MSH2	MutS Homolog 2	Protein Coding	12.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11859205 11231323 16826164 (more) 14518071 16327991
4	XPA	XPA, DNA Damage Recognition And Repair Factor	Protein Coding	12.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9180928
5	ODC1	Ornithine Decarboxylase 1	Protein Coding	12.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12201673 8640756 10874208 (more) 12757023 10917160
6	MSH6	MutS Homolog 6	Protein Coding	12.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16826164
7	PTCH1	Patched 1	Protein Coding	11.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15806168
8	FLCN	Folliculin	Protein Coding	11.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15657874 19234517
9	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	11.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17172848 16778799 17585316 (more) 15772091 19729838 20420824
10	MLH1	MutL Homolog 1	Protein Coding	11.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11859205 16826164
11	KRT20	Keratin 20	Protein Coding	11.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10937047 20007099
12	SERPINA3	Serpin Family A Member 3	Protein Coding	11.08	DISEASES inferred ¹⁴ ¹⁴
13	GLI1	GLI Family Zinc Finger 1	Protein Coding	10.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11378387 16158046
14	KRT1	Keratin 1	Protein Coding	10.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10365914
15	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	9.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18758463 12384550
16	GLI2	GLI Family Zinc Finger 2	Protein Coding	9.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12235001
17	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	9.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17610223 15343391 18453544 (more) 15141228 15343379
18	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	8.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16687919 17273161 19342899
19	TP63	Tumor Protein P63	Protein Coding	8.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17951196 20377670 15458526 (more) 15268709
20	GLA	Galactosidase Alpha	Protein Coding	8.51	DISEASES inferred ¹⁴
21	KRT13	Keratin 13	Protein Coding	8.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7681292
22	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	8.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15972968 12213282
23	NF1	Neurofibromin 1	Protein Coding	8.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10844550 16408192
24	CD34	CD34 Molecule	Protein Coding	7.58	DISEASES inferred ¹⁴
25	CD68	CD68 Molecule	Protein Coding	7.39	DISEASES inferred ¹⁴
26	COL1A1	Collagen Type I Alpha 1 Chain	Protein Coding	7.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9771975
27	TYR	Tyrosinase	Protein Coding	7.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15007389
28	ENO2	Enolase 2	Protein Coding	7.24	DISEASES inferred ¹⁴
29	ERCC3	ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit	Protein Coding	7.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9427533
30	KRT7	Keratin 7	Protein Coding	7.21	DISEASES inferred ¹⁴
31	PIP	Prolactin Induced Protein	Protein Coding	7.14	DISEASES inferred ¹⁴
32	MLANA	Melan-A	Protein Coding	7.11	DISEASES inferred ¹⁴
33	ERCC2	ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit	Protein Coding	7.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9427533
34	EWSR1	EWS RNA Binding Protein 1	Protein Coding	7.02	DISEASES inferred ¹⁴
35	TP53	Tumor Protein P53	Protein Coding	6.94	DISEASES inferred ¹⁴
36	CYLD	CYLD Lysine 63 Deubiquitinase	Protein Coding	6.89	DISEASES inferred ¹⁴
37	PLAG1	PLAG1 Zinc Finger	Protein Coding	6.86	DISEASES inferred ¹⁴

Sources

Variations for Skin Benign Neoplasm

Sources

Expression for Skin Benign Neoplasm

Search GEO for disease gene expression data for Skin Benign Neoplasm.

Sources

Pathways for Skin Benign Neoplasm

Pathways directly related to Skin Benign Neoplasm:

#	Pathway	Source
1	Defective CYP26C1 causes FFDD4	Reactome ⁶⁶

Pathways related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 23)

#	Super pathways	Score	Top Affiliating Genes
1	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.34	STAT3 HRAS FGFR3 BRAF
2	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.32	PTCH1 KRT1 HRAS GLI2 GLI1 BRAF
3	DNA Damage ³	12.27	XPA TP63 MSH6 MSH2 MLH1
4	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.12	STAT3 MSH6 MSH2 MLH1 HRAS FGFR3
5	Colorectal Cancer Metastasis ⁶⁴	11.77	STAT3 MSH6 MSH2 MLH1 BRAF
6	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.75	KRT14 KRT1 BRAF
7	DNA IR-damage and cellular response via ATR ⁷⁴	11.68	XPA MSH2 MLH1
8	Head and neck squamous cell carcinoma ⁷⁴	11.62	TP63 HRAS FGFR3
9	Osteoblast differentiation and related diseases ⁷⁴	11.55	PTCH1 GLI2 FGFR3
10	Thyroid stimulating hormone (TSH) signaling pathway ⁷⁴	11.51	STAT3 HRAS BRAF
11	Validated transcriptional targets of deltaNp63 isoforms ⁶¹	11.41	KRT14 KRT5 TP63
12	Busulfan Pathway, Pharmacodynamics ⁶⁰ Show member pathways Catalytic cycle of mammalian flavin-containing monooxygenases (FMOs) ⁷⁴ Defective FMO3 causes TMAU ⁶⁶ FMO oxidises nucleophiles ⁶⁶	11.38	STAT3 MSH2 MLH1
13	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.35	HRAS FGFR3 BRAF
14	Hedgehog signaling pathway ⁷⁴	11.32	PTCH1 GLI2 GLI1
15	Bladder cancer ⁷⁴	11.29	HRAS FGFR3 BRAF
16	Development_Hedgehog and PTH signaling pathways in bone and cartilage development ²²	11.26	PTCH1 GLI2 GLI1
17	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.23	BRAF HRAS STAT3
18	Hedgehog signaling events mediated by Gli proteins ⁶¹	11.21	GLI1 GLI2 PTCH1
19	Tumor suppressor activity of SMARCB1 ⁷⁴ Show member pathways GLI proteins bind promoters of Hh responsive genes to promote transcription ⁶⁶	11.14	PTCH1 GLI2 GLI1
20	Dopaminergic neurogenesis ⁷⁴	11.02	STAT3 GLI2 GLI1
21	Hair follicle development: organogenesis - part 2 of 3 ⁷⁴	10.9	PTCH1 GLI2 GLI1
22	EDA signaling in hair follicle development ⁷⁴	10.64	PTCH1 GLI1
23	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.39	XPA MSH6 MSH2 MLH1

Sources

GO Terms for Skin Benign Neoplasm

Cellular components related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mismatch repair complex	GO:0032300	9.33	MSH2 MLH1
2	GLI-SUFU complex	GO:1990788	9.13	GLI2 GLI1
3	MutSalpha complex	GO:0032301	8.92	MSH6 MSH2

Biological processes related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.33	TP63 ODC1 HRAS GLI2 GLI1 FGFR3
2	animal organ morphogenesis	GO:0009887	10.16	TP63 PTCH1 HRAS BRAF
3	stem cell proliferation	GO:0072089	10.02	TP63 PTCH1 GLI2
4	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	10.01	MSH6 MSH2 MLH1
5	intrinsic apoptotic signaling pathway	GO:0097193	9.99	FLCN HRAS MSH6
6	dorsal/ventral pattern formation	GO:0009953	9.98	PTCH1 GLI2 GLI1
7	epidermis development	GO:0008544	9.97	TP63 PTCH1 KRT5 KRT14
8	mismatch repair	GO:0006298	9.95	MSH6 MSH2 MLH1
9	pattern specification process	GO:0007389	9.91	TP63 PTCH1 GLI2
10	proximal/distal pattern formation	GO:0009954	9.91	TP63 GLI2 GLI1
11	positive regulation of helicase activity	GO:0051096	9.9	MSH2 MSH6
12	isotype switching	GO:0045190	9.88	MLH1 MSH2 MSH6
13	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.86	MSH2 MLH1
14	intermediate filament organization	GO:0045109	9.86	KRT5 KRT20 KRT14 KRT1
15	cerebellar cortex morphogenesis	GO:0021696	9.84	GLI2 GLI1
16	mammary gland duct morphogenesis	GO:0060603	9.77	GLI2 PTCH1
17	ventral midline development	GO:0007418	9.76	GLI2 GLI1
18	negative regulation of hh target transcription factor activity	GO:1990787	9.75	GLI2 GLI1
19	prostatic bud formation	GO:0060513	9.74	TP63 GLI2
20	maintenance of DNA repeat elements	GO:0043570	9.72	MSH6 MSH2
21	smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation	GO:0021938	9.7	GLI2 GLI1
22	somatic hypermutation of immunoglobulin genes	GO:0016446	9.63	MSH6 MSH2 MLH1
23	notochord regression	GO:0060032	9.54	GLI2 GLI1
24	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.5	MSH2 MLH1
25	prostate gland development	GO:0030850	9.35	TP63 PTCH1 GLI1
26	somatic recombination of immunoglobulin gene segments	GO:0016447	9.02	MSH6 MSH2 MLH1

Molecular functions related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin binding	GO:0003682	10.14	TP63 MSH6 MSH2 MLH1 GLI2 GLI1
2	MutLalpha complex binding	GO:0032405	9.76	MSH6 MSH2
3	oxidized purine DNA binding	GO:0032357	9.73	MSH6 MSH2
4	ATP-dependent DNA damage sensor activity	GO:0140664	9.73	MSH6 MSH2 MLH1
5	single guanine insertion binding	GO:0032142	9.67	MSH6 MSH2
6	damaged DNA binding	GO:0003684	9.63	XPA TP63 MSH6 MSH2
7	single thymine insertion binding	GO:0032143	9.62	MSH2 MSH6
8	mismatched DNA binding	GO:0030983	9.35	MSH6 MSH2 MLH1
9	guanine/thymine mispair binding	GO:0032137	9.1	MSH6 MSH2 MLH1